whitepaper
Article: Understanding potency in cell and gene therapy development
Read about the current state of the industry, challenges associated with potency assays and measuring product potency throughout the manufacturing process.
List view / Grid view
Targets
whitepaper
Article: Challenges in developing CAR T-cell therapies
Understand how quality control assays are being implemented in monitoring the development of CAR-T cells using high-throughput technologies in this article.
whitepaper
Application note: Droplet Digital polymerase chain reaction (ddPCR) is well suited for quantifying transgene copy number
This application note discusses why CAR T-cell therapy is so exciting, notes some common hurdles in development and manufacturing and proposes ddPCR technology as a solution for some of these issues.
news
New ALSV virus discovered in Swiss ticks
Researchers have detected Alongshan virus (ALSV) for the first time in Switzerland in ticks.
video
Webinar: Immunotherapy discovery & development
Discover key target cells for immunotherapy, how cells and processes can be assessed in vitro and approaches for selecting the most appropriate assay.
article
Nanotechnology: a new immuno-onocology weapon
This article outlines three innovative studies that use nanotechnology to deliver a new immunotherapy approach towards cancers.
article
Keeping T cells strong and improving cancer immunotherapy
The tumour microenvironment can prevent some T cells from carrying out their immunotherapeutic duties. In this Q&A, Dr Brian Shy, Clinical Instructor at the University of California, San Francisco (UCSF) Department of Laboratory Medicine, describes a recent study wherein he and fellow scientists discovered a strategy to strengthen T cells…
article
Silencing the messenger in elevated lipoprotein(a)
Elevated lipoprotein(a), or Lp(a), is a major risk factor for cardiovascular disease that affects one in five people worldwide, but currently lacks approved therapies. Here, Dr Giles Campion, EVP, Head of R&D and Chief Medical Officer of Silence Therapeutics, describes the company’s approach to developing an investigational siRNA therapy designed…
article
How to block trogocytosis and improve CAR T-cell therapy
Blocking a process called trogocytosis could enhance the ability of CAR T-cell therapies to treat cancer, according to research led by University of Pennsylvania scientists. In this Q&A, Dr Serge Fuchs, Elizabeth and William Whitney Clark Professor of Oncology at the University of Pennsylvania School of Veterinary Medicine, US, discusses…
article
A “hot” issue: TGF -β and checkpoint inhibitor resistance
In this article, Bryan Oronsky, Chief Development Officer, and Tony Reid, Chief Executive Officer of EpicentRx, explain how AdAPT-001 uses tumour cells as a factory to make the TGF-beta trap that it carries. This trap neutralises the immunosuppressive protein, transforming growth factor–β to ‘heat up’ tumours and sensitise them to…
news
CAR-T therapy becomes a powerful tool against an autoimmune disease like MS
US researchers have shown that CAR-T therapy can be used to eliminate unwanted cells that cause autoimmunity.
whitepaper
Whitepaper: Correlate protein expression with genomic data and IHC
Measure protein, DNA and RNA in FFPE tissue samples using rigorously IHC validated CST antibodies on the NanoString® nCounter® platform.
news
Where should the priority be for monkeypox vaccine allocations?
Canadian researchers underwent a modelling study to explore optimal allocation of vaccines against monkeypox virus (MPXV), that prioritises vaccines to larger networks with more initial infections and greater potential for spread is best.
article
Drug Target Review Immuno-oncology ebook 2022
In this ebook are articles on immune checkpoint inhibitors and enhancing CAR T-cell therapies.
article
Drug Target Review Cell and Gene Therapy Supplement 2022
This supplement focuses on how cell and gene therapy can target diseases such as cancer and reduce elevated lipoprotein(a).
